Streptococcus viridans bacteremia following autologous peripheral blood stem cell transplantation

Bone Marrow Transplantation
S BilgramiP J Tutschka

Abstract

A retrospective evaluation of 200 consecutive recipients of autologous peripheral blood stem cell transplantation was conducted to ascertain the incidence and outcome of Streptococcus viridans bacteremia as well as to determine the role of prophylactic ampicillin therapy in the peri-transplant setting. Viridans streptococci were isolated from the blood of 35 individuals at a median of 6 days (range 2-8 days) following stem cell infusion. The most common isolates were S. sanguis and S. mitis. All patients received ciprofloxacin orally during the peri-transplant period. Additionally, 79 patients received oral ampicillin prophylactically against gram-positive cocci. Although none of the patients suffered a fatal outcome, three individuals developed respiratory compromise requiring mechanical ventilation. Female sex proved to be the only independent risk factor for viridans streptococcal bacteremia (P=0.04). The shorter duration of neutropenia observed after stem cell transplantation did not impact on the incidence of S. viridans infections. Moreover, the prophylactic use of ampicillin failed to decrease the incidence of viridans sepsis and selected out organisms that were resistant to beta-lactam antibiotics.

Citations

Dec 6, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B S SohnC Suh
Jan 29, 2000·The New England Journal of Medicine·J S Serody
Nov 9, 2002·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·Sunday O AkintoyeJane C Atkinson
Nov 14, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A MarronF Gudiol
May 17, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Allan R Tunkel, Kent A Sepkowitz
Dec 4, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dana JaffeGenovefa A Papanicolaou
Oct 13, 2006·Current Opinion in Infectious Diseases·J Klastersky
Oct 13, 2006·Current Opinion in Infectious Diseases·A C Gilleece, L Fenelon
Aug 19, 2006·Critical Care Medicine·Ayman O Soubani
Apr 23, 2014·Emerging Infectious Diseases·Samuel A ShelburneAnthony R Flores
Jul 12, 2011·Leukemia & Lymphoma·Christos I Kosmidis, Pranatharthi H Chandrasekar
Nov 2, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·N M BlijlevensB E de Pauw
Aug 12, 2009·Infectious Disease Clinics of North America·Peter K Linden
May 21, 2009·Transplant Infectious Disease : an Official Journal of the Transplantation Society·K KohnoK Akashi
Jun 26, 2007·Pediatric Blood & Cancer·Anne F Reilly, Beverly J Lange
Nov 22, 2013·Transplant Infectious Disease : an Official Journal of the Transplantation Society·A SrinivasanR T Hayden
Aug 29, 2006·Seminars in Pediatric Infectious Diseases·Lauren Bruckner, Francis Gigliotti
Dec 18, 2013·Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology·Hani MawardiSook-Bin Woo
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adam GassasLillian Sung
Nov 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mario CrucianiCarlo Mengoli
Sep 4, 2018·Japanese Journal of Infectious Diseases·Sevgen Tanır BasaranogluMehmet Ceyhan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.